iX Biopharma's latest corporate presentation, prepared for the 23 Sept CITIC Securities International Investor Forum, contains several revealing details — especially when viewed against the extraordinary rise in iX's share price over the past year.

The event in Hong Kong was expected to attract more than 2,000 investors, policymakers, academics and business leaders across hundreds of one-on-one and group meetings.

The iX team comprised Chairman & CEO Eddy Lee, Chief Commercial Officer Eva Tan and Business Development Manager Daniel Chow.

In its presentation deck, iX itself highlights its stock's extraordinary rerating.

https://www.nextinsight.net/story-archive-mainmenu-60/949-2026/16898-ix-biopharma-why-investors-are-paying-s-600m-for-future-value